|
|
||||||||
1 Medical College of Georgia School of Medicine, Center for Healthcare Improvement, and Office of Biostatistics and Bioinformatics, Augusta.
2 Department of Veterans Affairs, Research Service Line, Augusta, Georgia.
3 School of Nursing, The Pennsylvania State University, University Park.
4 Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut.
Address correspondence to Donna M. Fick, RN, PhD, The Pennsylvania State University, School of Nursing, College of Health and Human Development, 307c Health and Human Development East, University Park, PA 16802-6509. E-mail: dmf21{at}psu.edu
| Abstract |
|---|
|
|
|---|
Methods. We used a 3-year cross-sectional, retrospective design with an administrative database from a large managed care organization. Four individually matched samples of 699 individuals each were selected for comparison purposes: delirium superimposed on dementia (DSD), dementia alone, delirium alone, and a control group with neither delirium nor dementia. The occurrence rate of DSD was calculated by measuring those individuals with a dementia diagnosis that were also coded with an International Classification of Diseases, Ninth Edition Clinical Modification (ICD-9 CM) code for delirium or delirium with dementia.
Results. Of the total sample of 76,688 persons aged 65 years or older in the managed care organization, 7347 (10%) were coded as having dementia, and an additional 763 (1%) as having delirium alone. Among the 7347 with dementia, 976 (13%) had DSD, representing 1.3% of the total sample. After log transformation of total costs and adjustment for multiple covariates, the adjusted mean total health care costs remained significantly higher for the DSD group than for all other groups.
Conclusions. This study is the first to report the occurrence rate of DSD in a community-dwelling population, and to demonstrate the substantial health care costs and utilization associated with DSD.
The few studies on delirium that have included persons with dementia demonstrate the high prevalence ranging from 22% to 89% (3) of DSD in both community and hospital populations, the frequent lack of recognition, and the efficacy of preventive strategies (4). Studies examining outcomes in patients with DSD have demonstrated increased rates of long-term cognitive impairment (2), increased rates of rehospitalization within 30 days (5,6), increased risk of admission to long-term care (6), and higher mortality rates (711). There have been a few studies examining pathophysiology of DSD and differences among dementia subtypes (12,13). Although they provided important preliminary information, these studies were generally limited by highly selected samples (e.g., dementia registry patients), small sample sizes, and unvalidated measures of delirium.
The objectives of the present study were: (a) to describe the occurrence rate of DSD in a large community-dwelling insured population of older adults and (b) to estimate the health care resource utilization and costs associated with DSD by examining matched comparison groups comprising patients with dementia alone or delirium alone, and a control group with neither dementia nor delirium.
| METHODS |
|---|
|
|
|---|
|
Study Approach
Prevalence rates were initially calculated based on the entire population, which was aged 65 or older. Prevalence of dementia was calculated by obtaining the membership status for those persons 65 years of age or older and then calculating the number of unique individuals having an ICD-9 diagnosis code for dementia during the enrollment period. The occurrence rate of DSD was calculated by measuring the number of individuals with a dementia diagnosis who also had an ICD-9 code for delirium or delirium with dementia during the study period. Subsequently, analyses were restricted to the four matched study groups.
Study Variables
The main independent variable was group status, that is, DSD group, a dementia-only group, a delirium-only group, or a neither dementia nor delirium (control) group. Descriptive and control variables selected for this study were identified from a review of the literature on delirium, dementia, and DSD and included medical diagnoses and comorbidities, medication-related variables, and demographics (1622). ICD-9 codes for medical diagnoses were taken from the discharge diagnosis listing (up to 10 per patient). Comorbidity was measured using the Deyo-adapted Charlson comorbidity index, designed for use with administrative databases (15). Comorbid conditions were identified using ICD-9 codes, then assigned a weighting that takes into account both the number and seriousness of different comorbid diseases (14). The Deyo-Charlson index has established reliability and validity in multiple populations (15).
Age was calculated based on birth date, as of January 1, 1998. Payor status was defined as: HMO, PPO, or FFS. HMO is a highly managed product that includes a primary care gatekeeper and minimal member co-payments. PPO is a moderately managed product where members receive an enhanced benefit and/or lower out-of-pocket costs in return for using the approved network of providers. FFS is a minimally managed product, and it generally includes deductibles. Nursing home visits were limited to short-stay skilled nursing home visits. Because our administrative database did not include socioeconomic status and race, the ZIP code of residence for each individual was used to approximate group proportions for these variables based on the Census 2000 database. Using previously published approaches (23,24), we obtained information that included: percentage of individuals living in rural communities within the ZIP code, median household income by age group within the ZIP code, and percentage of white, black, and Hispanic individuals within the ZIP code.
Health Care Utilization and Costs
Health care costs, for the purposes of this study, were based on the managed care organization claims data for payments in U.S. dollars made directly to the provider. Medical claims data for services performed in every setting were used. There were three different types of medical services from an insurance and/or payment standpoint (i.e., facility billed on UB-92 form, professional billed on HCFA 1500 form, or pharmacy). Places of treatment included inpatient, outpatient (including outpatient surgeries, radiology, outpatient clinics affiliated with hospitals, emergency rooms, homecare, and physician office visits). Costs included total, facility, provider, and prescription components. Individuals were community-dwelling at baseline; any nursing home visits were short-stay skilled nursing home visits. None of the patients were in the nursing home at baseline. Utilization included prescriptions in both inpatient and outpatient settings. Filled prescriptions are total numbers that included refills. Unique prescriptions do not include refills. All numbers presented are for the entire 3-year period.
Statistical Analyses
Chi-square tests, or Fisher's Exact tests as appropriate, were used to examine differences in rates of demographics, medical conditions, costs, and utilization among the four comparison groups. To examine differences among the four groups for costs and utilization, analysis of covariance (ANCOVA) was used with the four-level categorical variable: DSD, dementia only, delirium only, and control. To normalize the skewed cost data, a log transformation of the costs was used as the dependent variable in all ANCOVA models. Potential covariates in cost and utilization models included number of unique prescriptions filled, payor type, and community demographic data including proportion rural, median household income according to the age of the individual, proportion white, proportion black, and proportion Hispanic. All ANCOVA models incorporated the matched nature of the data by using a matched identifier in the models. The overall alpha level of 0.05 was used to determine statistical significance.
Model performance was evaluated by calculating the overall model R2 statistic. The independent effect of the four-level dementia and/or delirium variable was evaluated using partial r2, F value, and p value. A TukeyKramer multiple comparison adjustment to the overall alpha level was used to examine differences among the four groups post hoc. All statistical analyses were performed using SAS (version 8.2; SAS Institute, Cary, NC).
| RESULTS |
|---|
|
|
|---|
The demographic characteristics and medical conditions for the four matched study groups are shown in Table 1. These groups included 699 persons with DSD, 699 with dementia alone, 699 with delirium alone, and 699 in the control group. The majority of patients were female, white, and urban. The mean age of DSD and delirium alone patients was 76 years (74 years for the dementia alone and control groups). The control group has fewer individuals in FFS plans. Additionally, those individuals in the control group had fewer prescriptions filled than did those in the DSD, dementia-only, and delirium-only groups. There were no differences in race or income. Although significant differences in some of the matching variables persisted after the matching procedures, the differences were quantitatively small and of questionable clinical significance. Controlling for these matching variables in further analyses of total costs did not affect the overall results.
|
Among those persons with DSD, the delirium diagnoses preceded the dementia diagnosis in 33.48% (234/699) of cases and followed the dementia diagnosis in 66.52% (465/699) of cases. The mean time between the dementia and delirium diagnoses among those persons whose delirium diagnosis preceded the dementia diagnosis was 6.40 months (standard deviation [SD] = 7.73, range 0.0332.33 months). The mean time between the dementia and delirium diagnoses among those individuals whose delirium diagnosis followed the dementia diagnosis was 8.72 months (SD = 9.48, range 035.27 months). We further analyzed the proportion of costs that occurred after the delirium diagnosis in our 3-year study period in the delirium groups. Of the total costs, 40% (SD 34%) in the delirium-only group and 50% (SD 32%) in the DSD group occurred after the initial delirium diagnosis. However, because this is a cross-sectional study of secondary data, we cannot be sure that a delirium diagnosis did not occur in the months or years preceding our study period.
Table 2 shows the unadjusted total, facility, provider, and prescription costs (in U.S. dollars) and utilization across the four groups, with the DSD group having higher utilization and costs. Total costs over the 3-year period averaged $9,565 for the DSD group, $7,556 for the dementia-only group, $9,422 for the delirium-only group, and $4,765 for the control group.
|
|
|
|
| DISCUSSION |
|---|
|
|
|---|
The 10% prevalence of dementia alone and 13% occurrence rate of delirium in patients with dementia in this study are higher than what has been reported in other administrative studies, but lower than what was found in some recent prospective studies (3,6). Gutterman and colleagues (25) examined dementia in managed Medicare and found a prevalence rate of dementia of 0.86% in those 60 years old or older. Baker found a prevalence of delirium of 25% in persons with Alzheimer's disease using a medical record review, whereas Marcantanio reported a prevalence or 66% in hospitalized persons with dementia (19,21,25,26). In older adults in the United States, the overall occurrence found for DSD is actually higher than the prevalence for other chronic conditions, such as congestive heart failure, which is analogous in having low overall prevalence rates of 2%6%, and which is a costly and devastating chronic condition that affects older adults disproportionately (2729).
Costs and utilization were significantly higher in the DSD group than in the dementia-only and the control groups. Costs in the DSD and delirium-only groups were almost twice as high as those in the control group, and significantly higher than those in the dementia-only group. A previous review of DSD (3) highlighted the potential costs savings from early recognition and management of delirium, and this study suggests that recognizing and treating delirium in persons with dementia may have important cost implications. Our underlying hypothesis is that delirium increases costs and utilization (beyond dementia alone). Our matching on comorbidity was one important methodologic approach to address differences in utilization rates. However, we cannot eliminate the possibility that higher rates of utilization might have resulted in higher rates of detection of the delirium and dementia diagnoses. A recent literature review by Bloom and colleagues of 21 studies (30) estimating the costs of Alzheimer's disease highlighted the difficulties of attributing specific medical services and their costs to each dementia diagnosis, but also points out that costs are likely to rise in the future with a greater need for evaluation of cost variability. The present study is important for describing the cost impact of delirium on dementia by examining comparable dementia cohorts with and without delirium.
Some important caveats deserve comment. The major limitations of this study include the use of claims data, the classification of cases on diagnosis codes reported on paid claims, and the use of retrospective data for acute and chronic conditions. The major limitation of a cross-sectional design and the use of administrative claims data is that the temporal ordering of the diagnoses and utilization rates is not known. Although this remains a major limitation in our study, we have provided data on the order of the dementia and delirium diagnoses in our claims data. Studies that rely on medical record or administrative data review for the diagnoses of delirium are likely to underestimate the prevalence of delirium compared to prospective (direct) measures of delirium (31,32). It is also possible that some persons without dementia and delirium were falsely coded as such on claims (79). As with other studies of economic costs, our estimates of costs were skewed. We used the alternative models of square root and log transformation, which produced similar results. In addition, we did not discount our costs. Lastly, the cross-sectional nature of the study limits the ability to make any causal inferences regarding the medical conditions associated with DSD. Our inability to establish the temporal ordering of the medical diagnoses and delirium in this study is another limitation of the administrative data used for this study.
Despite these limitations, this is the first large-scale study to address the problem of DSD in a community sample and to measure cost and utilization of DSD. A recent survey of physician management of delirium found that physicians varied widely in the management of this problem (33), and, despite over 20 years of research on delirium, we still do not know the natural history of and effective treatment strategies for persons with dementia who develop delirium. Additionally, a recent study (34) found administrative data to be able to accurately measure clinical quality even in the face of significant data loss. Future studies are needed to evaluate prospectively the risk factors for DSD, and to evaluate and test intervention strategies for prevention of this condition. The present study highlights the importance of the common and costly problem of DSD for the older community-dwelling population.
| Acknowledgments |
|---|
We thank Richard Vanden Heuvel and Marc Gottlieb of Blue Cross Blue Shield of Georgia for data support; Dennis Shea, PhD, for cost analysis review; and Judy Johnson and R. C. Robinson, Jr., for manuscript preparation.
This research was presented in part at the Gerontological Society of America's 55th Annual Scientific Meeting in Boston, Massachusetts, in November 2002.
| Footnotes |
|---|
Received December 18, 2003
Accepted March 17, 2004
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
D. B. Hogan MD, P. Bailey MD, S. Black MD, A. Carswell MSc PhD, H. Chertkow MD, B. Clarke MD, C. Cohen BA MD, J. D. Fisk PhD, D. Forbes RN PhD, M. Man-Son-Hing MSc MD, et al. Diagnosis and treatment of dementia: 4. Approach to management of mild to moderate dementia Can. Med. Assoc. J., October 7, 2008; 179(8): 787 - 793. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Bellelli, S. Morghen, and M. Trabucchi AUTHORS' RESPONSE TO LETTER FROM LAURILA AND COLLEAGUES J. Gerontol. A Biol. Sci. Med. Sci., October 1, 2008; 63(10): 1124 - 1126. [Full Text] [PDF] |
||||
![]() |
K. H. Pitkala, J. V. Laurila, T. E. Strandberg, H. Kautiainen, H. Sintonen, and R. S. Tilvis Multicomponent Geriatric Intervention for Elderly Inpatients With Delirium: Effects on Costs and Health-Related Quality of Life J. Gerontol. A Biol. Sci. Med. Sci., January 1, 2008; 63(1): 56 - 61. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Bellelli, G. B. Frisoni, R. Turco, E. Lucchi, F. Magnifico, and M. Trabucchi Delirium Superimposed on Dementia Predicts 12-Month Survival in Elderly Patients Discharged From a Postacute Rehabilitation Facility J. Gerontol. A Biol. Sci. Med. Sci., November 1, 2007; 62(11): 1306 - 1309. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. T. Pun and E. W. Ely The Importance of Diagnosing and Managing ICU Delirium Chest, August 1, 2007; 132(2): 624 - 636. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|---|
| All GSA journals | The Gerontologist |
| Journals of Gerontology Series B: Psychological Sciences and Social Sciences | |